| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H50O2 |
| Molecular Weight | 454.7275 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC(C)=O)C(C)C
InChI
InChIKey=IZEUIYYDWBKERE-ZRODXFKISA-N
InChI=1S/C31H50O2/c1-8-23(20(2)3)10-9-21(4)27-13-14-28-26-12-11-24-19-25(33-22(5)32)15-17-30(24,6)29(26)16-18-31(27,28)7/h9-11,20-21,23,25-29H,8,12-19H2,1-7H3/b10-9+/t21-,23-,25+,26+,27-,28+,29+,30+,31-/m1/s1
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Sample Use Guides
Cells, transfected with retinoic X receptor (RXR), hRXR alpha , were treated with agonist or agonist plus 10 uM stigmasterol acetate (StigAc) and 24 h later harvested and processed, and luciferase activities normalized as before. The agonist ligandsused were FXR, CDCA(100 uM); pregnane X receptor (PXR), peroxisome proliferator-activated receptor gamma (PPAR gamma), rosiglitazone(1 uM). Increasing concentrations of StigAc (0–10 uM) suppress CDCA-activated FXR with an IC50 of 5–10 uM, which is well below the physiologic range of Stig levels found in the serum of patients with serological evidence of PNAC. In addition to suppressing CDCA-activated FXR-LBD activity, StigAc also suppresses ligand-activated PXR-LBD activity. Except for a slight increase in RXR alpha LBD activity, StigAc has no discernible effect on any other NRLBD tested.
SUBSTANCE RECORD
